


NHMRC DIABETES AND DEMENTIA RESEARCH

2000 2000–2023 outputs, outcomes, and impact pathways tracked 2024

\$679 M in 2011–2024 NHMRC awards for diabetes
\$622 M in 2011–2024 NHMRC awards for dementia

OUTPUTS

Publications



Diabetes

4.2% of NHMRC publication output

Dementia

3% of NHMRC publication output

The citation impact of these publications is more than **2 times** the global average.



490

Number of distinct diabetes interventions* to which NHMRC contributed.

445

Number of distinct dementia interventions.*



15.5%

of NHMRC Diabetes papers shared their data, compared to 12.9% for funders worldwide.

1,000+

Number of patent families† citing NHMRC diabetes and dementia research.

OUTCOMES



13
Dementia and diabetes startups linked to NHMRC funding

Products include Cogstate Brief Battery, a key tool in Alzheimer's research, and PromarkerD, a tool for predicting rapid renal decline in patients with diabetes.

101

Number of commercialised or trademarked diabetes interventions* to which NHMRC has contributed.

44

Number of commercialised or trademarked dementia interventions.*



153

Clinical trials for dementia

216

Clinical trials for diabetes (2005–2024)

NHMRC-funded dementia and diabetes research saw higher levels of rare clinical guideline uptake events than comparable global funders, with 4% and 8% of publications cited, respectively.

PATHWAYS TO IMPACT

NHMRC-supported prevention programs have helped people with diabetes achieve lifestyle changes, including weight losses of 8% or more and empowered these individuals with greater knowledge and control over their disease.

NHMRC funding of art therapy interventions or drugs such as resveratrol or canagliflozin led to greater patient well-being and quality of life.

The NHMRC-supported drug canagliflozin also reduced hospitalizations.

Current NHMRC dementia and diabetes research leverages tools from AI, bioengineering, gene editing, or the health-environment nexus to lay the groundwork for future health innovations.



Preliminary evidence shows clear health, economic and societal impacts of NHMRC dementia and diabetes research.

* Medical, technological, educational, or lifestyle strategies for prevention, management or treatment.

† A group of related patent applications filed for the same invention, sharing a priority date.